Treatment of SURgical wounds with a novel, innovative Peptide-hydrogel Antimicrobial wound Spray
| Reference number | |
| Coordinator | Amferia AB |
| Funding from Vinnova | SEK 5 000 000 |
| Project duration | March 2024 - February 2027 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
Deliver an antimicrobial wound spray to prevent surgical site infections. The Spray is based on antimicrobial peptides that are permanently attached to amphiphilic hydrogel particles and will be the first spray that eliminates antimicrobial resistant strains without harming human tissue, induces coagulation and enhances wound healing. The project team will optimize the antimicrobial formulation, create a functional spraying device, and perform efficacy studies in vitro and in vivo. The goal is a Spray that is preclinically validated and ready for clinical validation.
Expected effects and result
The main results of the project will be a pre-clinically validated antimicrobial spray and a preclinical data set demonstrating the in-vitro and in vivo safety and efficacy of the spray for the treatment and prevention of surgical site wound infections. Additionally, documentation for a clinical study will be prepared by the end of this project. Thus, the antimicrobial spray will be ready for clinical studies directly following this project.
Planned approach and implementation
AMFERIA will be responsible for the formulation development, pre-clinical efficacy and safety validation according to ISO standards, and the clinical validation, and for leading commercialisation efforts following clinical validation. MEDSPRAY will be responsible for development and subsequent manufacturing of the delivery device on a larger scale. During the project, both partners will work closely for development and testing.